

Early recognition of cardiovascular disease

Gepubliceerd: 01-05-2018 Laatste bijgewerkt: 19-03-2025

The early stages of cardiovascular disease (CVD) generally cause non-specific or atypical symptoms that patients often do not spontaneously mention to their general practitioner. This makes that new onset CVD is easily missed. A more proactive...

Ethische beoordeling	Niet van toepassing
Status	Anders
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON24396

Bron

NTR

Verkorte titel

RED-CVD

Aandoening

Cardiovasculaire ziekten
Hart- en vaatziekten
Atriumfibrilleren
Coronairlijden
Hartfalen
Cardiovascular disease
atrial fibrillation
coronary artery disease
heart failure

Ondersteuning

Primaire sponsor: University Medical Center Utrecht

Overige ondersteuning: Nederlandse Hartstichting

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The number of newly detected cases with CVDs (heart failure, atrial fibrillation or coronary artery disease) in both arms, and the subsequent targeted therapies these new cases received.

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: The early stages of cardiovascular disease (CVD) generally cause non-specific or atypical symptoms that patients often do not spontaneously mention to their general practitioner. This makes that new onset CVD is easily missed. A more proactive diagnostic strategy has the potential to uncover these frequently missed early stages, thus creating an opportunity for early intervention that may prevent progression into chronic CVD or devastating acute cardiovascular events. This is of particular importance for cardiovascular diseases with evidence-based therapies known to improve prognosis, such as coronary artery disease (CAD), atrial fibrillation (AF) and heart failure (HF).

Previous studies have shown that patients with type 2 diabetes (T2D) or chronic obstructive lung disease (COPD) are at highly increased risk of developing CVD. In the current study, we will test a newly developed Early Diagnosis Strategy, aimed at these high risk patients and blended in with the primary care disease management programs these patients routinely participate in.

Objectives: Firstly, to compare the diagnostic yield of the Early Diagnosis Strategy to usual care, in terms of detection and subsequent treatment of previously unrecognized CAD, AF and HF. Secondly, to demonstrate the added diagnostic value of extensive family and reproductive history taking and that of three (novel) biomarkers. Thirdly, to demonstrate that the Early Diagnosis Strategy is cost-effective compared to usual care.

Study design: A cluster randomized diagnostic trial will be conducted in 40 primary care practices, including adults who are enrolled in the disease-management programs for COPD

or T2D. The main outcome of this study is the number of newly detected cases with CVDs in both arms, and the subsequent targeted therapies these new cases received. The Early Diagnosis Strategy will be blended in with the routine visits that are part of these disease-management programs. The Early Diagnosis Strategy is a two-stage intervention, consisting of a questionnaire which is, in case of positive answers, followed by physical examination, electrocardiography, and N-terminal natriuretic peptide measurement NT-proBNP. In case of findings suggestive of CVD, additional investigations will be performed by the GP or cardiologist after referral, in line with existing guidelines. In addition, questionnaires on detailed family history and, for women, reproductive history will be filled out in the intervention arm and the added diagnostic value to the Early Diagnosis Strategy will be calculated. Furthermore, extra blood samples from all participants in the intervention arm will be drawn during the same venapuncture used for NT-proBNP-measurement, to investigate the diagnostic value of several cardiac biomarkers, i.e. high sensitive troponin I (hs-Tn I) , ST-2 and growth differentiation factor 15 (GDF-15), for the detection of the target CVDs.

Doel van het onderzoek

The early stages of cardiovascular disease (CVD) generally cause non-specific or atypical symptoms that patients often do not spontaneously mention to their general practitioner. This makes that new onset CVD is easily missed. A more proactive diagnostic strategy has the potential to uncover these frequently missed early stages, thus creating an opportunity for early intervention that may prevent progression into chronic CVD or devastating acute cardiovascular events. This is of particular importance for cardiovascular diseases with evidence-based therapies known to improve prognosis, such as coronary artery disease (CAD), atrial fibrillation (AF) and heart failure (HF).

Previous studies have shown that patients with type 2 diabetes (T2D) or chronic obstructive lung disease (COPD) are at highly increased risk of developing CVD, and that 20-65% of these patients have 'concealed' CVD. In the current cluster-randomized diagnostic trial, we will test a newly developed Early Diagnostic Strategy, aimed at these high risk patients and blended in with the primary care disease management programs these patients routinely participate in.

We hypothesize that the Early Diagnosis Strategy will uncover 10% new cases of CAD, AF or HF in patients with T2D or COPD; an additional 5% to the 5% expected to be detected with usual care.

Onderzoeksopzet

At inclusion, all patients will fill out the EQ-5D-5L questionnaire on health-related quality of life. Patients in the control arm will receive care as usual within the primary care disease management program (DMP) for COPD or T2D. Patients in the intervention arm will undergo the Early Diagnosis Strategy. Prior to their next routine visit that will have been scheduled as part of the DMP they participate in, they will be asked to fill out the Early Diagnosis Questionnaire on signs and symptoms suggestive of CVDs. In addition, they will be asked to

fill out questionnaires on family history and, for women, reproductive history. During the scheduled routine visit, the GP or practice nurse will review their answers. In case of positive answers, the patient will undergo electrocardiography (ECG), NT-proBNP measurement and a physical examination. And extra vial of blood will be drawn during the same venapuncture used for NT-proBNP measurement and serum samples will be stored in a biobank. In case of elevated NT-proBNP or abnormalities found with ECG or physical examination, the patient will be referred to a cardiologist for further investigations and treatment according to guidelines. One year after the initial routine visit took place, follow-up data (new diagnoses, referrals, medication prescribed, outpatient visits and hospital admissions) will be collected in both arms. The stored serum samples will be thawed and three cardiac biomarkers will be measured (GDF-15, hs-TnI, ST-2).

Onderzoeksproduct en/of interventie

Patients in the intervention arm will undergo the Early Diagnosis Strategy. The Early Diagnosis Strategy consists of a questionnaire that can be filled in online prior to their routine visit to their general practitioner and which, in case of a positive answer to one of the questions, is followed by focused physical examination (inspection of legs and neck and auscultation of heart and lungs), electrocardiography and blood-drawing for BNP-measurement. In patients who undergo blood drawing for BNP-measurement, an extra 10 mL of blood will be drawn during the same venapuncture, and stored in a sub-biobank. Part of this will be used at the end of the study to measure three (novel) cardiac biomarkers. The other part will remain in the biobank for future cardiac biomarker studies. Patients in the intervention arm will also be asked to fill in additional short questionnaires on female-specific history and family-specific history.

Contactpersonen

Publiek

Postbus 85500
Amy Groenewegen

Universitair Medisch Centrum Utrecht
Room number 6.104
Huispostnummer Stratenum 6.131
Utrecht 3508 GA
The Netherlands
088 75 69 619

Wetenschappelijk

Postbus 85500
Amy Groenewegen

Universitair Medisch Centrum Utrecht
Room number 6.104
Huispostnummer Stratenum 6.131
Utrecht 3508 GA
The Netherlands
088 75 69 619

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Currently enrolled in a primary care (chronic) disease management program for either COPD or T2D
2. Age 18 years or over
3. Willing to sign informed consent

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Not proficient in Dutch or having severe cognitive impairment (i.e. not able to understand and correctly fill in the questionnaire)
2. Having a triple diagnosis of HF, CAD and AF. Confirmed with echocardiography in case of HF, with coronary angiography, exercise-test, stress-echo, stress MRI, SPECT-CT/MIBI or calcium score > 100 on CT-scan in case of CAD, with electrocardiography in case of AF.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Open / niet geblindeerd

Controle: Geneesmiddel

Deelname

Nederland

Status: Anders

(Verwachte) startdatum: 01-12-2018

Aantal proefpersonen: 1300

Type: Onbekend

Ethische beoordeling

Niet van toepassing

Soort: Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 52511

Bron: ToetsingOnline

Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL7161
NTR-old	NTR7360
CCMO	NL65798.041.18
OMON	NL-OMON52511

Resultaten